Compare RUN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | NVAX |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2015 | 1996 |
| Metric | RUN | NVAX |
|---|---|---|
| Price | $6.94 | $10.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $14.64 | $14.22 |
| AVG Volume (30 Days) | 7.4M | ★ 8.0M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 113.35 | ★ 309.76 |
| EPS | ★ 1.04 | N/A |
| Revenue | $858,578,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | 12.97 | ★ 64.69 |
| 52 Week Low | $7.17 | $6.20 |
| 52 Week High | $21.95 | $13.39 |
| Indicator | RUN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 47.76 |
| Support Level | N/A | $7.93 |
| Resistance Level | $8.95 | $11.73 |
| Average True Range (ATR) | 0.34 | 1.17 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 2.39 | 18.01 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.